|
1.
|
GM LauerBD WalkerHepatitis C virus
infectionN Engl J
Med3454152200110.1056/NEJM20010705345010711439948
|
|
2.
|
DL ThomasLB SeeffNatural history of
hepatitis CClin Liver
Dis9383398200510.1016/j.cld.2005.05.00316023972
|
|
3.
|
JG McHutchisonEJ LawitzML
ShiffmanPeginterferon alfa-2b or alfa-2a with ribavirin for
treatment of hepatitis C infectionN Engl J
Med361580593200910.1056/NEJMoa080801019625712
|
|
4.
|
AJ ThompsonAJ MuirMS
SulkowskiInterleukin-28B polymorphism improves viral kinetics and
is the strongest pretreatment predictor of sustained virologic
response in genotype 1 hepatitis C
virusGastroenterology139120129.e18201010.1053/j.gastro.2010.04.013
|
|
5.
|
CL ThioDL ThomasM CarringtonChronic viral
hepatitis and the human
genomeHepatology31819827200010.1053/he.2000.431610733534
|
|
6.
|
AJ MuirJD BornsteinPG
KillenbergPeginterferon alfa-2b and ribavirin for the treatment of
chronic hepatitis C in blacks and non-Hispanic whitesN Engl J
Med35022652271200410.1056/NEJMoa03250215163776
|
|
7.
|
HS ConjeevaramMW FriedLJ
JeffersPeginterferon and ribavirin treatment in African American
and Caucasian American patients with hepatitis C genotype
1Gastroenterology131470477200610.1053/j.gastro.2006.06.00816890601
|
|
8.
|
MW FriedML ShiffmanKR ReddyPeginterferon
alfa-2a plus ribavirin for chronic hepatitis C virus infectionN
Engl J Med347975982200210.1056/NEJMoa02004712324553
|
|
9.
|
MP MannsJG McHutchisonSC
GordonPeginterferon alfa-2b plus ribavirin compared with interferon
alfa-2b plus ribavirin for initial treatment of chronic hepatitis
C: a randomised
trialLancet358958965200110.1016/S0140-6736(01)06102-511583749
|
|
10.
|
M LaggingG AskariehF NegroResponse
prediction in chronic hepatitis C by assessment of IP-10 and
IL28B-related single nucleotide polymorphismsPLoS
One6e17232201110.1371/journal.pone.001723221390311
|
|
11.
|
DL ThomasCL ThioMP MartinGenetic variation
in IL28B and spontaneous clearance of hepatitis C
virusNature461798801200910.1038/nature0846319759533
|
|
12.
|
D GeJ FellayAJ ThompsonGenetic variation
in IL28B predicts hepatitis C treatment-induced viral
clearanceNature461399401200910.1038/nature0830919684573
|
|
13.
|
V SuppiahM MoldovanG AhlenstielIL28B is
associated with response to chronic hepatitis C interferon-alpha
and ribavirin therapyNat
Genet4111001104200910.1038/ng.44719749758
|
|
14.
|
Y TanakaN NishidaM SugiyamaGenome-wide
association of IL28B with response to pegylated interferon-alpha
and ribavirin therapy for chronic hepatitis CNat
Genet4111051109200910.1038/ng.44919749757
|
|
15.
|
X LiuZ WangJ YuG LeiS WangThree
polymorphisms in interleukin-1beta gene and risk for breast cancer:
a meta-analysisBreast Cancer Res
Treat124821825201010.1007/s10549-010-0910-320437198
|
|
16.
|
WB ZhouDQ XueXA LiuQ DingS WangThe
influence of family history and histological stratification on
breast cancer risk in women with benign breast disease: a
meta-analysisJ Cancer Res Clin
Oncol13710531060201110.1007/s00432-011-0979-z21499874
|
|
17.
|
J NattermannM VogelHD NischalkeGenetic
variation in IL28B and treatment-induced clearance of hepatitis C
virus in HIV-positive patients with acute and chronic hepatitis CJ
Infect Dis203595601201110.1093/infdis/jiq09821257738
|
|
18.
|
J LauJP IoannidisCH SchmidQuantitative
synthesis in systematic reviewsAnn Intern
Med127820826199710.7326/0003-4819-127-9-199711010-000089382404
|
|
19.
|
R DerSimonianN LairdMeta-analysis in
clinical trialsControl Clin
Trials7177188198610.1016/0197-2456(86)90046-23802833
|
|
20.
|
N MantelW HaenszelStatistical aspects of
the analysis of data from retrospective studies of diseaseJ Natl
Cancer Inst22719748195913655060
|
|
21.
|
CN HayesM KobayashiN AkutaHCV
substitutions and IL28B polymorphisms on outcome of peg-interferon
plus ribavirin combination
therapyGut60261267201110.1136/gut.2010.22349521068134
|
|
22.
|
A RauchZ KutalikP DescombesGenetic
variation in IL28B is associated with chronic hepatitis C and
treatment failure: a genome-wide association
studyGastroenterology1381338134545
e17201010.1053/j.gastro.2009.12.05620060832
|
|
23.
|
E AparicioM PareraS FrancoN Perez-AlvarezC
TuralB ClotetMA MartinezIL28B SNP rs8099917 is strongly associated
with pegylated interferon-alpha and ribavirin therapy treatment
failure in HCV/HIV-1 coinfected patientsPLoS
One5e13771201010.1371/journal.pone.001377121048934
|
|
24.
|
J GrebelyK PetoumenosM HellardPotential
role for interleukin-28B genotype in treatment decision-making in
recent hepatitis C virus
infectionHepatology5212161224201010.1002/hep.2385020803561
|
|
25.
|
ML YuCF HuangJF HuangRole of
interleukin-28B polymorphisms in the treatment of hepatitis C virus
genotype 2 infection in Asian
patientsHepatology53713201110.1002/hep.2397621254157
|
|
26.
|
CS HsuSJ HsuHC ChenAssociation of IL28B
gene variations with mathematical modeling of viral kinetics in
chronic hepatitis C patients with IFN plus ribavirin therapyProc
Natl Acad Sci USA10837193724201110.1073/pnas.110034910821321200
|
|
27.
|
A MoghaddamE MelumN ReintonH Ring-LarsenH
VerbaanK BjøroO DalgardIL28B genetic variation and treatment
response in patients with hepatitis C virus genotype 3
infectionHepatology53746754201110.1002/hep.2415421374656
|
|
28.
|
JY ChenCY LinCM WangIL28B genetic
variations are associated with high sustained virological response
(SVR) of interferon-alpha plus ribavirin therapy in Taiwanese
chronic HCV infectionGenes
Immun12300309201110.1038/gene.2011.121346780
|
|
29.
|
TM ScherzerH HoferAF StaettermayerEarly
virologic response and IL28B polymorphisms in patients with chronic
hepatitis C genotype 3 treated with peginterferon alfa-2a and
ribavirinJ
Hepatol54866871201110.1016/j.jhep.2010.08.02421145807
|
|
30.
|
N SakamotoM NakagawaY TanakaAssociation of
IL28B variants with response to pegylated-interferon alpha plus
ribavirin combination therapy reveals intersubgenotypic differences
between genotypes 2a and 2bJ Med
Virol83871878201110.1002/jmv.22038
|
|
31.
|
M KurosakiY TanakaN NishidaPre-treatment
prediction of response to pegylated-interferon plus ribavirin for
chronic hepatitis C using genetic polymorphism in IL28B and viral
factorsJ Hepatol54439448201110.1016/j.jhep.2010.07.037
|
|
32.
|
T KawaokaCN HayesW OhishiPredictive value
of the IL28B polymorphism on the effect of interferon therapy in
chronic hepatitis C patients with genotypes 2a and 2bJ
Hepatol54408414201110.1016/j.jhep.2010.07.03221112660
|
|
33.
|
PY BochudS BibertF NegroIL28B
polymorphisms predict reduction of HCV RNA from the first day of
therapy in chronic hepatitis CJ HepatolFeb2011(E-pub ahead of
print).
|
|
34.
|
C SarrazinS SusserA DoehringImportance of
IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3
infected patientsJ
Hepatol54415421201110.1016/j.jhep.2010.07.04121112657
|
|
35.
|
A MangiaAJ ThompsonR SantoroAn IL28B
polymorphism determines treatment response of hepatitis C virus
genotype 2 or 3 patients who do not achieve a rapid virologic
responseGastroenterology1398218277
e1201010.1053/j.gastro.2010.05.07920621700
|
|
36.
|
JJ McCarthyJH LiA ThompsonReplicated
association between an IL28B gene variant and a sustained response
to pegylated interferon and
ribavirinGastroenterology13823072314201010.1053/j.gastro.2010.02.00920176026
|
|
37.
|
JA PinedaA CaruzA RiveroPrediction of
response to pegylated interferon plus ribavirin by IL28B gene
variation in patients coinfected with HIV and hepatitis C virusClin
Infect Dis51788795201010.1086/65623520804372
|
|
38.
|
MA Montes-CanoJR Garcia-LozanoC
Abad-MolinaInterleukin-28B genetic variants and hepatitis virus
infection by different viral
genotypesHepatology523337201010.1002/hep.2362420578254
|
|
39.
|
M HondaA SakaiT YamashitaHepatic ISG
expression is associated with genetic variation in interleukin 28B
and the outcome of IFN therapy for chronic hepatitis
CGastroenterology139499509201010.1053/j.gastro.2010.04.04920434452
|
|
40.
|
ES De AraujoH DahariSJ CotlerTJ LaydenAU
NeumannCE MeloAA BaronePharmacodynamics of PEG-IFN-[alpha]-2a and
HCV response as a function of IL28B polymorphism in
HIV/HCV-coinfected patientsJ Acquir Immune Defic
Syndr5695992011
|
|
41.
|
JM DarlingJ AerssensG FanningQuantitation
of pretreatment serum interferon-gamma-inducible protein-10
improves the predictive value of an IL28B gene polymorphism for
hepatitis C treatment
responseHepatology531422201110.1002/hep.2405621254158
|
|
42.
|
T ReibergerK RutterA FerlitschPortal
pressure predicts outcome and safety of antiviral therapy in
cirrhotic patients with HCV infectionClin Gastroenterol
Hepatol9602608201110.1016/j.cgh.2011.03.00221397726
|
|
43.
|
L YangY LuoJ WeiS HeIntegrative genomic
analyses on IL28RA, the common receptor of interferon-λ1, -λ2 and
-λ3Int J Mol Med25807812201020372826
|
|
44.
|
L YangJ WeiS HeIntegrative genomic
analyses on interferon-λs and their roles in cancer predictionInt J
Mol Med252993042010
|
|
45.
|
KK YanM GuirgisT DinhJ GeorgeA DevA LeeA
ZekryTreatment responses in Asians and Caucasians with chronic
hepatitis C infectionWorld J
Gastroenterol1434163420200810.3748/wjg.14.341618528940
|
|
46.
|
CH LiuCJ LiuCL LinPegylated
interferon-alpha-2a plus ribavirin for treatment-naive Asian
patients with hepatitis C virus genotype 1 infection: a
multicenter, randomized controlled trialClin Infect
Dis4712601269200810.1086/592579
|
